To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the cookie policy

When you see uveal melanoma progress, think
collaboratively

While guidelines for the management of uveal melanoma (UM) are emerging, evidence-based treatments for progressive disease are still needed.^1,2

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Uveal Melanoma were first published in 2018 and were most recently updated in May 2020.^3,4

Other national guidelines include^5-9:

Guidance from the National Cancer Institute (NCI)
Uveal Melanoma UK National Guidelines (NICE-accredited)
The French Cancer Society
The Netherlands’ Recommendations for Uveal Melanomas Treatment Guidelines
A consensus-based guideline from Canada

A recent analysis of UM guidelines published between 2004 and 2019 appraised the methodological quality of assessed guidelines using AGREE II and AGREE-REX tools.¹

Click here to access the full publication.

Poor prognosis for advanced disease

While effective therapies targeting the primary tumor in the eye have been developed, up to half of patients develop metastatic disease, most commonly spreading to the liver.^1,10 The prognosis for metastatic uveal melanoma (mUM) remains poor, with a median survival of up to 12 months.^2,11-13

≈50% of patients with mUM

survive for one year after diagnosis.¹³

Think uveal melanoma brochure

Please download the brochure for more information on uveal melanoma.

Download

Surveillance defined by metastatic risk

Studies have indicated that the risk for metastasis varies and is influenced by clinical and histological characteristics of the patient and the tumor, including^14-16:

tumor diameter
degree of pigmentation
high mitotic rate
somatic mutations in the tumor
tumor thickness
ciliary body involvement
advanced age
male gender

Guidelines recommend surveillance by a multidisciplinary team to identify mUM, but acknowledge that patients should understand both the benefits and the risks of surveillance.^4,6,8,17 Unfortunately, surveillance and early detection have generally not been linked to improved outcomes,¹⁸ likely due to the lack of universally accepted effective therapies for mUM.^10,12,13 Several factors do support surveillance, and its use is likely to become more important as more effective treatments for metastatic disease become available.¹⁹

Therapeutic options
for mUM offer
only modest efficacy,
and clinical trials
are currently
the recommended
course of treatment,
when clinically
appropriate.^4,10,12,13

Liver-specific imaging* is common

due to the high rate of metastasis to the liver. Liver function tests are likely inadequate based on current evidence.^3,6,8,18

*Eg, ultrasound, magnetic resonance imaging, and computed tomography.

Taking a multidisciplinary approach

While no approved therapy has demonstrated a substantial benefit specifically for patients with mUM,^2,12 guidelines recommend a multidisciplinary approach to the management of metastatic disease.^4,6,8,17

Multidisciplinary teams may include expertise from the following areas^6,8,17:

Medical oncology
Ophthalmology
Radiology and radiotherapy
Pathology
Surgical oncology
Nursing specialist
Hepatology

A collaborative approach may help optimize outcomes for patients with mUM.¹⁰

References:

Steeb T, Hayani KM, Fӧrster P, et al. Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument. J Cancer Res Clin Oncol. 2020;146(4):1‌0‌79-10‌88. doi:10.10‌07/s00‌432‌-02‌0-03‌14‌1-w
Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol. 2018;10:1758‌8340‌18‌757175. doi:10.1177/1758‌834‌01875‌7175
Barker CA, Salama AK. New NCCN Guidelines for uveal melanoma and treatment of recurrent or progressive distant metastatic melanoma. J Natl Compr Canc Netw. 2018;16(5.5):646-650. doi:10.6004/jnccn.2018.0042
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Uveal Melanoma V.1.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed August 6, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Mathis T, Cassoux N, Tardy M, et al. Management of uveal melanomas, guidelines for oncologists. Article in French. Bull Cancer. Published online September 11, 2018. 2018;10‌5(10):967-980. doi:10.10‌16/‌j.bulca‌n.20‌18.07‌.011
The Netherlands’ recommendations for uveal melanoma (eye melanoma) treatment guidelines. Published 2017.
Weis E, Salopek TG, McKinnon JG, et al. Management of uveal melanoma: a consensus-based provincial clinical practice guideline. Curr Oncol. 2016;23(1):e57-e64. doi:10.3‌747/co.23.28‌59
Nathan P, Cohen V, Coupland S, et al. Uveal melanoma UK national guidelines. Eur J Cancer. 2015;51(16):2‌40‌4-24‌12. doi:10.1016/j.ejca.2015.07.013
Intraocular (uveal) melanoma treatment (PDQ®)–health professional version. National Cancer Institute. Updated December 17, 2019. Accessed April 15, 2020. https://ww‌w.cancer.go‌v/types/ey‌e/hp/intraocular-melanoma-tre‌atment-pdq
Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38-44. doi:10.1136/bjo‌phthalm‌ol-20‌16-30‌034
Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. 2017;31(8):724-743. doi:10.1101/gad.296962.117
Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):13‌70-1‌380. doi:10.1093/annonc/mdz176
Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. Published online. 2019;29(6):561-568. doi:10.1097/C‌MR.00‌0000‌00000‌00575
Vaquero-Garcia J, Lalonde E, Ewens KG, et al. PRiMeUM: a model for predicting risk of metastasis in uveal melanoma. Invest Ophthalmol Vis Sci. 2017;58(10):4‌096‌-4‌105. doi:10.1167/iovs.17-22255
Corrêa ZM. Assessing prognosis in uveal melanoma. Cancer Control. 2016;23(2):93-98. doi:10.11‌77/10‌3‌2748‌160‌2300‌202
Gill HS, Char DH. Uveal melanoma prognostication: from lesion size and cell type to molecular class. Can J Ophthalmol. 2012;47(3):246-253. doi:10.1016/j.jcjo.2012.03.038
Nathan P, Cohen V, Coupland S, et al. Uveal melanoma national guidelines. Melanoma Focus. Published January 2015. Accessed April 15, 2020. http://melanomafocus.c‌om/wp-content/uploads/20‌15/01/Uveal-Melanoma-Nationa‌l-Guidelines-Full-v5.3.pdf
Kivelä T, Simpson ER, Grossniklaus HE, et al. Uveal melanoma. In: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer; 2017:805-817.
Francis JH, Patel SP, Gombos DS, Carvajal RD. Surveillance options for patients with uveal melanoma following definitive management. In: Dizon DS, ed. American Society of Clinical Oncology Educational Book. Vol 33. American Society of Clinical Oncology; 2013:382-387. doi:10.14694/EdB‌ook_AM.‌20‌13.33.382
Onken MD, Worley LA, Char DH, et al. Collaborative Ocular Oncology Group report no. 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. Published online August 1, 2013. 201‌2;119‌(8):159‌6-16‌03. doi:10.10‌16/j.ophtha.20‌12.0‌2.017

The information and other content contained on this website are not intended to be, nor should they be, used as medical advice, diagnosis, or treatment. Each patient must be evaluated, diagnosed, and treated based upon that individual patient’s specific circumstances.

The information contained on this website is intended for healthcare professionals. By clicking the "Continue" button, you are acknowledging that you are a healthcare professional.

Continue

You are now leaving this website.

Click “Continue” to proceed to an external website not sponsored or controlled by Immunocore.

Select “Cancel” to return to ThinkUvealMelanoma.com.

Continue Cancel

Thank you for signing up.

You will be notified when new information becomes available at ThinkUvealMelanoma.com.

Thank you.

You have been unsubscribed from ThinkUvealMelanoma.com.

Please tell us what you think

Before you leave, will you take a moment to answer five quick questions? Your feedback will help us maintain and improve ThinkUvealMelanoma.com.

Yes No

Submit

Thank you

We appreciate your taking the time to share your valuable opinion. Your thoughts on ThinkUvealMelanoma.com will help us continually update and enhance the site.

Close window

Before you share, please be reminded that this website
should be shared only with other healthcare professionals.

Continue Cancel

When you see uveal melanoma progress, think
collaboratively

While guidelines for the management of uveal melanoma (UM) are emerging, evidence-based treatments for progressive disease are still needed.^1,2

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Uveal Melanoma were first published in 2018 and were most recently updated in May 2020.^3,4

Other national guidelines include^5-9:

Guidance from the National Cancer Institute (NCI)

Uveal Melanoma UK National Guidelines (NICE-accredited)

The French Cancer Society

The Netherlands’ Recommendations for Uveal Melanomas Treatment Guidelines

A consensus-based guideline from Canada

Poor prognosis for advanced disease

Think uveal melanoma brochure

Surveillance defined by metastatic risk

NCCN Guidelines^® for Uveal Melanoma recommend stratification by risk for distant metastasis to determine frequency of systemic imaging during follow-up.⁴

Risk stratification to determine the frequency of follow-up systemic imaging should be based on the highest risk factor present⁴

LOW RISK⁴

Surveillance imaging recommendation^a:

MEDIUM RISK⁴

Surveillance imaging recommendation^a:

HIGH RISK⁴

Surveillance imaging recommendation^a:

Taking a multidisciplinary approach

A collaborative approach may help optimize outcomes for patients with mUM.¹⁰

Watch Bertil Damato, MD, PhD, discuss standards of care

Get the latest updates in your inbox

Unsubscribe

When you see uveal melanoma progress, thinkcollaboratively

While guidelines for the management of uveal melanoma (UM) are emerging, evidence-based treatments for progressive disease are still needed.1,2

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Uveal Melanoma were first published in 2018 and were most recently updated in May 2020.3,4

Other national guidelines include5-9:

Guidance from the National Cancer Institute (NCI)

Uveal Melanoma UK National Guidelines (NICE-accredited)

The French Cancer Society

The Netherlands’ Recommendations for Uveal Melanomas Treatment Guidelines

A consensus-based guideline from Canada

Poor prognosis for advanced disease

Think uveal melanoma brochure

Surveillance defined by metastatic risk

NCCN Guidelines® for Uveal Melanoma recommend stratification by risk for distant metastasis to determine frequency of systemic imaging during follow-up.4

Risk stratification to determine the frequency of follow-up systemic imaging should be based on the highest risk factor present4

LOW RISK4

Surveillance imaging recommendationa:

MEDIUM RISK4

Surveillance imaging recommendationa:

HIGH RISK4

Surveillance imaging recommendationa:

Taking a multidisciplinary approach

A collaborative approach may help optimize outcomes for patients with mUM.10

Watch Bertil Damato, MD, PhD, discuss standards of care

Get the latest updates in your inbox

Unsubscribe

You are now leaving this website.

Thank you for signing up.

Thank you.

Please tell us what you think

Thank you

Get the latest updates in your inbox

Unsubscribe

When you see uveal melanoma progress, think
collaboratively

While guidelines for the management of uveal melanoma (UM) are emerging, evidence-based treatments for progressive disease are still needed.^1,2

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Uveal Melanoma were first published in 2018 and were most recently updated in May 2020.^3,4

Other national guidelines include^5-9:

NCCN Guidelines^® for Uveal Melanoma recommend stratification by risk for distant metastasis to determine frequency of systemic imaging during follow-up.⁴

Risk stratification to determine the frequency of follow-up systemic imaging should be based on the highest risk factor present⁴

LOW RISK⁴

Surveillance imaging recommendation^a:

MEDIUM RISK⁴

Surveillance imaging recommendation^a:

HIGH RISK⁴

Surveillance imaging recommendation^a:

A collaborative approach may help optimize outcomes for patients with mUM.¹⁰